{
    "organizations": [],
    "uuid": "2f173634bb177d3336e11f815f951460af3227a3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/idUSFWN1RG0JK",
    "ord_in_thread": 0,
    "title": "REFILE-Palatin Technologies Presents Preclinical Data On Investigational Treatment For IBD",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "(Corrects headline to say “IBD”, not “IBS”)\nApril 3 (Reuters) - Palatin Technologies Inc:\n* PALATIN TECHNOLOGIES PRESENTS PRECLINICAL ORAL FORMULATION DATA ON PL-8177, AN INVESTIGATIONAL MELANOCORTIN RECEPTOR 1 AGONIST FOR INFLAMMATORY BOWEL DISEASES\n* PALATIN TECHNOLOGIES INC - SUBJECT DOSING IS ONGOING WITH TOP LINE DATA CURRENTLY EXPECTED IN Q3 OF 2018 FOR PL-8177 Source text for Eikon:\n ",
    "published": "2018-04-03T19:37:00.000+03:00",
    "crawled": "2018-04-03T15:15:36.015+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "corrects",
        "headline",
        "say",
        "ibd",
        "ibs",
        "april",
        "reuters",
        "palatin",
        "technology",
        "inc",
        "palatin",
        "technology",
        "present",
        "preclinical",
        "oral",
        "formulation",
        "data",
        "investigational",
        "melanocortin",
        "receptor",
        "agonist",
        "inflammatory",
        "bowel",
        "disease",
        "palatin",
        "technology",
        "inc",
        "subject",
        "dosing",
        "ongoing",
        "top",
        "line",
        "data",
        "currently",
        "expected",
        "q3",
        "source",
        "text",
        "eikon"
    ]
}